These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28433254)

  • 1. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
    Lewis R; Drebin JA; Callery MP; Fraker D; Kent TS; Gates J; Vollmer CM
    HPB (Oxford); 2013 Jan; 15(1):49-60. PubMed ID: 23216779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
    Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
    Shaib WL; Narayan AS; Switchenko JM; Kane SR; Wu C; Akce M; Alese OB; Patel PR; Maithel SK; Sarmiento JM; Kooby DA; El-Rayes BF
    Cancer; 2019 Jan; 125(1):57-67. PubMed ID: 30457666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.
    Kim Y; Kim SC; Song KB; Kim J; Kang DR; Lee JH; Park KM; Lee YJ
    HPB (Oxford); 2016 Apr; 18(4):325-31. PubMed ID: 27037201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
    Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
    Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
    Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Single-Institution Experience.
    Batukbhai B; Herman JM; Zahurak M; Laheru DA; Le DT; Wolfgang CL; Zheng L; De Jesus-Acosta A
    Pancreas; 2021 Jan; 50(1):64-70. PubMed ID: 33370024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
    Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
    HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.